samedan logo
 
 
 
spacer
home > ebr > autumn 2020 > boston diary – day 144
PUBLICATIONS
European Biopharmaceutical Review

Boston Diary – Day 144

When I wrote my last column, ‘Run for the Roses’, the race for a COVID-19 vaccine was just getting underway. Now, the preliminary reports are coming in almost daily. Multiple projects, featuring diverse technologies, show early and encouraging progress. Large-scale clinical trials will demonstrate how well the different approaches work in large numbers of people. While the candidates apparently do elicit antibodies, one key question is effectiveness. Will the vaccine provide immunity; in what fraction of the population; and for how long? Achieving herd immunity for COVID-19 is estimated to require an immunity rate somewhere between that of flu and measles vaccines – and we still face significant unknowns in production and distribution.

As a time-honoured stop-gap measure, many hospitals throughout the world have turned to convalescent blood plasma for the more serious cases. Anecdotally, it has provided improvement in patient outcomes and did not potentiate cytokine storms. Post hoc analysis of immunoglobulin G quantitation and patient outcomes for matched subjects strongly suggest efficacy. However, donor plasma is a limited commodity. A number of biopharmaceutical companies have launched programmes to develop synthetic antibodies, which can complement vaccine therapy if they can be made cost-effective.

The soothsayer in Shakespeare’s play, Julius Caesar, was on my mind as the COVID-19 pandemic began to spread. The ‘Ides of March’ arrived, and my office started to work from home. In our region, as in many others, our state government provided guidelines for social distancing, business closures – except for essential operations – and other public health measures. The savings in auto mileage and daily commute time did have a certain appeal. Online meetings soon became the new normal. However, the excessive, back-to-back web meetings every morning get a little tedious.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Emile Bellott is a member of the EBR Industry Advisory Board, a graduate of the Harvard Business School, US, and an industry consultant with experience in the biotech and biopharma industry.
spacer
Emile Bellott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Murata’s RFID technology helps Bayer revolutionise transparency of its pharmaceutical supply chain

Hoofddorp, Netherlands: Murata ID Solutions has helped life science giant Bayer’s Italian division, Bayer S.p.A., leverage radio frequency identification (RFID) tracking in the first large-scale application of the technology in the pharmaceutical supply chain. The pioneering project has enabled Bayer to gain real-time visibility over its distribution processes to optimise customer service, improve product security and asset tracking, and enhance response to unprecedented threats.
More info >>

White Papers

Clinical Trial Site Contracting: The Conservative, Progressive and Hybrid Models

DrugDev

For the last 20 years, pharmaceutical companies have turned to a variety of clinical outsourcing solutions to reduce costs and improve timelines, enabling them to focus on their core value of research and development. In today’s tightly competitive market, companies are constantly striving for ways to further cut costs and reduce study startup cycle times, while maintaining quality. One of the key cost factors in global R&D spending, estimated at around $102 billion per Kalorama market research, is the cost of conducting clinical trials. CRO’s, which account for about 30% of the total R&D spending, have risen to the challenge of the clinical, technical and administrative management of these trials. But some pharmaceutical companies question how much control to relinquish to vendor partners, especially in the legal arena, due to potential ramifications.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement